Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
Background. Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. Objectives. Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum en...
Saved in:
| Main Authors: | Hande Erman, Engin Beydogan, Seher Irem Cetin, Banu Boyuk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2020/3534042 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiometabolic risk factors in Turkish children with hepatosteatosis
by: Ahmet Aslan, et al.
Published: (2019-10-01) -
Detection of Impaired Cognitive Function in Rat with Hepatosteatosis Model and Improving Effect of GLP-1 Analogs (Exenatide) on Cognitive Function in Hepatosteatosis
by: Oytun Erbaş, et al.
Published: (2014-01-01) -
Association of plasma endocan levels with metabolic parameters and predictive value of endocan for the development of complications in patients with type 2 diabetes mellitus: An observational study
by: Kenana Ljuca, et al.
Published: (2024-12-01) -
The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses
by: Sandeep Samethadka Nayak, et al.
Published: (2025-05-01) -
IDO-Dependent Tryptophan Metabolites and Endocan as Effective Diagnostic Biomarkers for Pregnancy with Pulmonary Hypertension
by: Peng G, et al.
Published: (2025-07-01)